Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
前收盤價
US$9.17
+US$0.17 · +1.89%
盤中時間採用ET。市場資料可能有所延遲。
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
日內區間
目前US$9.17
52週區間
目前US$9.17
盤中時間採用ET。市場資料可能有所延遲。
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
日內區間
目前US$9.17
52週區間
目前US$9.17
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 8.22億 USD | 7.99億 USD | 7.47億 USD | 4.61億 USD | 4.64億 USD |
| 銷貨成本 | 2.71億 USD | 2.54億 USD | 2.6億 USD | 1.24億 USD | 1.15億 USD |
| 毛利 | 5.52億 USD | 5.46億 USD | 4.86億 USD | 3.37億 USD | 3.5億 USD |
| 研究與開發 | 5711.2萬 USD | 7364.3萬 USD | 8023.1萬 USD | 4906.5萬 USD | 4962.1萬 USD |
| 銷售、一般及管理費用 | 4.56億 USD | 5.33億 USD | 5.3億 USD | 3.09億 USD | 2.91億 USD |
| 營業費用 | 6.2億 USD | 6.31億 USD | 6.25億 USD | 3.5億 USD | 3.58億 USD |
| 利息支出 | 1748.8萬 USD | 2963.1萬 USD | 863.1萬 USD | 128.8萬 USD | 183.7萬 USD |
| 折舊和攤銷 | 8325.5萬 USD | 7596.2萬 USD | 6056.1萬 USD | 3207.5萬 USD | 3309.6萬 USD |
| 營業利益 | −6847.1萬 USD | −8461.9萬 USD | −1.39億 USD | −1326.8萬 USD | −831.5萬 USD |
| 淨利 | −9219.2萬 USD | −1.26億 USD | −1.51億 USD | −1974.9萬 USD | −3837.9萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$13.40
上漲空間 46.13%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1140.71萬0.00%2.3兆 USD0.03%US$381.94—
iShares Russell 2000 ETFIWM947.89萬0.01%787.4億 USD0.19%US$278.94—
Vanguard Extended Market ETFVXF443.44萬0.00%954億 USD0.05%US$235—
Vanguard Russell 2000 ETFVTWO218.51萬0.01%180億 USD0.06%US$112.66—
Dimensional - US Small Cap ETFDFAS193.14萬0.01%338.69億 USD0.31%US$78.35—
Schwab U.S. Small-Cap ETFSCHA191.48萬0.01%218.24億 USD0.03%US$32.79—
iShares U.S. Medical Devices ETFIHI181.39萬0.05%——US$51.74—
Fidelity Enhanced Small Cap ETFFESM145.34萬0.02%64.1億 USD0.28%US$45.46—
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
Vanguard Russell 2000 ETFVTWO
Dimensional - US Small Cap ETFDFAS
Schwab U.S. Small-Cap ETFSCHA
iShares U.S. Medical Devices ETFIHI
Fidelity Enhanced Small Cap ETFFESMAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。